Background {#Sec1}
==========

Acute kidney injury (AKI) is an important complication in severe malaria that is associated with increased mortality in both paediatric \[[@CR1]--[@CR6]\] and adult populations \[[@CR7]--[@CR10]\]. However, until recently, the incidence of AKI in paediatric malaria was under-appreciated as few children develop signs of overt renal failure and creatinine testing is not routinely available in resource-constrained settings. Despite significant progress in reducing malaria incidence and mortality \[[@CR11]\], case fatality rates in severe disease remain high, and the identification of an effective adjunctive therapy is a research priority.

Decreased bioavailable nitric oxide is a common feature in both children and adults with severe malaria, and clinical trials to increase nitric oxide (NO) have been conducted \[[@CR12]--[@CR14]\]. Although there has been no conclusive benefit demonstrated in human trials designed to increase bioavailable NO, infusion of [l]{.smallcaps}-arginine in adults with severe malaria improved endothelial recovery \[[@CR12]\], and iNO delivered at 80 ppm was associated with reduced risk of fine motor impairment in children under 5 years of age at 6 month follow up \[[@CR15]\].

Despite early reports that inhaled NO (iNO) was associated with increased splanchnic and renal blood flow \[[@CR16]\], a meta-analysis of adults with acute respiratory distress syndrome found that iNO treatment was associated with a 50% increased risk of developing AKI (relative risk, 95% CI 1.50, 1.11--2.02) \[[@CR17]\]. This has been confirmed in another meta-analysis including non-ARDS patients \[[@CR18]\], but the effect was strongest in patients with ARDS with prolonged exposure and a high cumulative dose. There are limited reports evaluating iNO and renal safety in children. Previously, an increase in the overall incidence of AKI (relative risk, 95% CI 1.36, 1.03--1.90, p = 0.026) was reported in children treated with iNO \[[@CR6]\]. However, there was no association between iNO and AKI when restricting the analysis to children who developed AKI after treatment was initiated.

Chitinase-3-like 1 protein (CHI3L1) is a 39 kDa secreted glycoprotein produced by a variety of cell types in response to inflammation, including activated macrophages, neutrophils, and fibroblasts. CHI3L1 is highly expressed in healthy kidney tissue \[[@CR19]\] and is freely filtered by the glomerulus. CHI3L1 is also secreted by activated macrophages in the kidney upon stress or damage \[[@CR20]\]. Elevated levels of CHI3L1 have been reported in Ugandan children with severe malaria, and further elevated in fatal malaria \[[@CR21]\]. Co-culture of human peripheral blood mononuclear cells with *Plasmodium falciparum*-infected erythrocytes in vitro induced CHI3L1 transcription and secretion of CHI3L1 protein \[[@CR21]\]. While CHI3L1 was elevated by day 5 infection in an experimental model of cerebral malaria, genetic disruption of *Chi3l1* did not affect inflammatory responses or outcome \[[@CR21]\].

In this secondary analysis of an iNO intervention trial, CHI3L1 was investigated as a biomarker of morbidity and mortality in paediatric severe malaria, the longitudinal kinetics of CHI3L1 were explored in children hospitalized with severe malaria, and the impact of iNO therapy on CHI3L1 normalization was evaluated.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The study was conducted between 2011 and 2013 at the Jinja Regional Referral Hospital in Jinja, Uganda. All children were treated with intravenous artesunate followed by oral artemisinin-based combination therapy. Inclusion criteria were age 1--10 years, *P. falciparum* by RDT (First Response Malaria Ag. HRP2/pLDH Combo Rapid Diagnostic Test, Premier Medical Corporation Limited, India), selected severe malaria criteria (decreased consciousness, repeated seizures, prostration, and/or respiratory distress), and plasma sample available for CHI3L1 testing. Exclusion criteria included: known chronic illness, severe malnutrition, known haemoglobinopathy, prior treatment with quinine in the emergency department, suspicion of acute bacterial meningitis. Study gas was delivered continuously by non-rebreather mask for up to 72 h, as previously described \[[@CR13], [@CR22]\].

Acute kidney injury {#Sec4}
-------------------

Creatinine and BUN were assessed at the point of care using i-STAT CHEM8+ or Crea cartridges (Abbott Laboratories, Saint-Laurent, Québec). Creatinine measured by i-STAT is calibrated traceable to the isotype dilution mass spectrometry reference measurement and is free of interference from haemoglobin, bilirubin, and glucose \[[@CR23]\]. Estimated glomerular filtration rate (eGFR) was calculated using the Bedside Schwartz equation, using a constant for children (k = 0.413) \[[@CR24]\]. Presence of AKI was determined retrospectively using KDIGO guidelines \[[@CR25]\]. Children were considered to have AKI if they had either a ˃26 μmol/L rise in creatinine within 48 h or \> 1.5-fold increase in creatinine from estimated baseline. Baseline creatinine was estimated assuming a normal GFR of 120 mL/min/1.73 m^2^ and using the Schwartz equation to back calculate creatinine based on the child's height. The children with AKI were further classified by stage: stage 1 (risk; 1.5--1.9-fold increase in creatinine from nadir), stage 2 (injury; 2.0--2.9-fold increase), and stage 3 (failure; greater than 3.0-fold increase, single value greater than 354 µmol/L during hospitalization, or an eGFR of \< 35 mL/min/1.73 m^2^) \[[@CR25]\]. The incidence of AKI in this cohort has been previously reported \[[@CR6]\].

Laboratory testing {#Sec5}
------------------

K~2~ EDTA anticoagulated plasma samples were collected daily from children during hospitalization (day 1--4), and at follow up (day 14) and stored at − 80 °C until testing. Cystatin C and CHI3L1 were measured by ELISA (DuoSet, R&D Systems, Burlington, Canada) with the investigator blinded to treatment group and outcome \[[@CR6]\]. LDH activity was measured using a colorimetric assay according to manufacturer's protocol (BioVision, Milpitas, CA, USA). The limit of detection for CHI3L1 was 4.5 ng/mL with inter- and intra-assay reproducibility of 5.9 and 6.3%, respectively. Markers of intravascular haemolysis (haem, haemopexin) \[[@CR26]\], endothelial activation (Ang-2, sICAM-1) \[[@CR27]\], and inflammation (CRP, sTREM-1, CXCL10/IP-10) were measured by ELISA as previously described \[[@CR27], [@CR28]\]. Biomarkers were selected for analysis based on an established association with disease severity and mortality in Ugandan children with severe malaria \[[@CR27], [@CR28]\].

Statistical analysis {#Sec6}
--------------------

Data were analysed using Stata/SE v14.0, GraphPadPrism v7.03, and R \[[@CR29]\]. For access to the dataset see Additional file [1](#MOESM1){ref-type="media"}. Continuous data are presented as median (interquartile range, IQR) and analyzed using Wilcoxon rank sum test or non-parametric test for trend. Categorical data are presented as n (%) and analysed using Pearson's Chi Square or Fisher's exact test, as appropriate. To compare biomarker levels at admission, Spearman's non-parametric correlation was used. To assess the relationship between CHI3L1 and mortality, generalized linear models were used opting first for a log-binomial model with robust standard errors. In the event of failed convergence Poisson regression was used with robust standard errors.

R \[[@CR29]\] and lme4 \[[@CR30]\] were used to perform a linear mixed effects (LME) analysis of in-hospital longitudinal course of log (CHI3L1) over time in patients without AKI and with different stages of AKI. Time, nitric oxide treatment arm, and AKI stage were entered as fixed effects with and without interaction terms. Intercepts and slopes were modeled for each subject as random effects. The intercept for treatment arm was constrained to zero at baseline as children were randomly allocated to treatment arm. Visual inspection of residual plots did not reveal deviations from homoscedasticity or normality. p values were obtained by likelihood ratio tests of the full model (including AKI stage) against the model without AKI stage.

Results {#Sec7}
=======

CHI3L1 levels at presentation are associated with disease severity and AKI {#Sec8}
--------------------------------------------------------------------------

Levels of CHI3L1 were available for 159 children at admission (Fig. [1](#Fig1){ref-type="fig"}). A description of the population is included in Table [1](#Tab1){ref-type="table"}. The median age of children was 2.0 years and 56% were male. At admission, children with CHI3L1 levels in the highest quartile had a median of 5 severe malaria criteria compared to 4 in children with the lowest three quartiles (p \< 0.0001) \[[@CR31]\]. Children with elevated CHI3L1 also had higher lactate (p = 0.001), lower bicarbonate, (p \< 0.0001) and higher Cystatin C (p = 0.001) and BUN levels (p = 0.025). Children with CHI3L1 levels in the highest quartile were more likely to have AKI (p = 0.034), and there was a strong relationship between CHI3L1 and severity of AKI with 5.9% of children with CHI3L1 levels in the lowest three quartiles having stage 3 AKI compared to 28.2% of children with CHI3L1 levels in the highest quartile having stage 3 AKI (p \< 0.0001). The relationship between CHI3L1 levels and kidney function was further explored using linear regression to investigate the relationship between creatinine, Cystatin C. and BUN as dependent variables and log~10~(CHI3L1) levels at admission as the independent variable (Table [2](#Tab2){ref-type="table"}). A log~10~ increase in CHI3L1 was significantly associated with creatinine, Cystatin C, and BUN following adjustment for age and sex. When adjusting for other measures of kidney function, log~10~(CHI3L1) remained independently associated with an increase in Cystatin C following correction for creatinine (beta, 95% CI 0.17, 0.05--0.30, p = 0.008), but not BUN. The relationship between log~10~(CHI3L1) and BUN was not significant when adjusting for either creatinine or Cystatin C (p \> 0.05), and the relationship between log~10~(CHI3L1) and creatinine was not significant when adjusting for Cystatin C or BUN (p \> 0.05).Fig. 1Flow chart of study population Table 1Patient characteristics based on quartiles of CHI3L1 levels at admissionCohortCHI3L1Q123 versus Q4, p valueQ123 (n = 120)Q4 (n = 39)Patient demographics Age, years2.0 (1.0, 3.0)2.0 (1.0, 3.0)2.0 (1.0, 3.0)0.825 Sex, males89 (56.0)68 (56.7)21 (53.8)0.450 Weight, kg11.0 (9.0, 13.0)11.0 (9.0, 13.0)11.0 (9.0, 13.0)0.893 Height, cm79 (71, 90)79 (71, 90)80 (70, 88)0.850 Weight-for-age z− 1 (− 2, 0)− 1 (− 2, 0)0 (− 2, 0)0.247 Height-for-age z− 2 (− 3, 0)− 2 (− 3, 0)− 2 (− 3, − 1)0.575Clinical parameters at admission Temperature37.9 (37.0, 38.8)38.0 (37.0, 39.0)37.8 (37.0, 38.4)0.304 Heart rate161 (144, 179)161 (142, 177)162 (153, 181)0.186 Respiratory rate48 (38, 62)46 (36, 60)55 (44, 66)0.056 Systolic BP110 (100, 120)110 (100, 120)110 (100, 125)0.740 Diastolic BP60 (50, 70)60 (50, 70)60 (50, 70)0.932 Coma95 (59.7)67 (55.8)28 (71.8)0.077 Convulsions126 (79.2)95 (79.2)31 (79.5)0.966 Severe anaemia104 (65.4)74 (61.7)30 (76.4)0.082 Haemoglobinuria26 (16.4)20 (16.7)6 (15.4)0.403 Jaundice25 (15.8)17 (14.3)8 (20.5)0.355 Deep breathing74 (46.5)54 (45.0)20 (51.3)0.494 Shock14 (8.8)9 (7.5)5 (12.8)0.308 Severe malaria criteria4 (3, 6)4 (3, 5)5 (4, 6)0.0004Laboratory tests Parasitaemia25,280 (2620, 78,840)23,000 (2640, 72,320)36,320 (2525, 115,600)0.264 Lactate, μmol/L3.6 (2.1, 6.5)3.1 (2.0, 5.5)5.5 (3.0, 10.3)0.001 Glucose, μmol/L6.7 (5.6, 8.1)6.8 (5.8, 8.1)6.3 (4.2, 8.5)0.106 Haemoglobin, g/dL4.7 (3.0, 6.4)4.8 (3.0, 6.7)4.6 (3.1, 5.4)0.341 WBC11.6 (7.5, 19.4)11.30 (7.65, 19.30)12.50 (6.70, 20.30)0.746 Platelets × 10^3^71 (38, 124)73 (42, 133)60 (29, 114)0.186 HCO3^−^17.3 (13.0, 20.1)18.3 (14.8, 20.2)12.4 (10.5, 18.0)0.0001 Na^+^137 (135, 140)138 (135, 140)137 (134, 140)0.289 K^+^4.1 (3.7, 4.5)4.1 (3.7, 4.4)4.3 (3.8, 4.9)0.125 Cl^−^108 (104, 112)108 (104, 112)110 (105, 114)0.501 Creatinine, μmol/L31 (23, 41)30 (24, 38)34 (23, 58)0.260 Cystatin C1041 (778, 1313)954 (754, 1191)1247 (1054, 1545)0.001 BUN16.0 (9.0, 27.5)14.0 (9.0, 25.0)25.5 (10.8, 42.0)0.025Treatment group Received iNO76 (47.8)53 (44.2)23 (59.0)0.108Acute kidney injury AKI70 (44.3)47 (39.5)23 (59.0)0.034AKI stage  088 (55.7)72 (60.5)16 (41.0)\< 0.0001  138 (24.1)32 (26.9)6 (15.4)  214 (8.9)8 (6.7)6 (15.4)  318 (11.4)7 (5.9)11 (28.2) Incident AKI^a^22 (13.9)17 (14.3)5 (12.8)0.819Outcome Discharge with disability7 (6.7)6 (7.2)1 (4.6)1.000 Death, in-hospital14 (8.8)7 (5.8)7 (18.0)0.020 Death, 6 months^b^22 (17.3)13 (13.5)9 (29.0)0.048Data presented as median (interquartile range) or n (%). Continuous data analyzed using Mann--Whitney U test and dichotomous variables analysed using Pearson's Chi Square or Fisher's exact test^a^Incident AKI defined as AKI that developed following admission to hospital (n = 55 cases of AKI were present on admission)^b^Outcome available for 127 children Table 2Relationship between log~10~CHI3L1 levels and kidney functionDependent variableUnadjusted beta (95% CI)p valueAdjusted beta^a^ (95% CI)p valueCreatinine13.97 (5.16, 22.77)0.00213.51 (4.66, 22.36)0.003Cystatin C0.28 (0.13, 0.44)\< 0.00010.28 (0.13, 0.44)\< 0.0001BUN10.21 (3.92, 16.51)0.00210.23 (3.87, 16.60)0.002^a^Adjusted for age and sex

Admission CHI3L1 is independently associated with in-hospital and all-cause 6 month mortality {#Sec9}
---------------------------------------------------------------------------------------------

CHI3L1 levels were compared at admission with subsequent in-hospital mortality and all-cause 6 month mortality. CHI3L1 levels in the highest quartile were significantly associated with death (Table [1](#Tab1){ref-type="table"}). Further, median CHI3L1 levels were higher among children who died in-hospital than those who survived (p = 0.023, Wilcoxon rank sum test) and children who died by 6 months follow up compared to those known to survive (p = 0.046). By multivariable analysis, a one unit increase in log~10~(CHI3L1) was associated with a 4.10-fold increased risk of in-hospital death (95% CI 1.32--12.75, p = 0.015) following adjustment for treatment arm and AKI status using a log binomial model. Further, a one unit increase in log~10~(CHI3L1) was associated with a 3.21-fold increased risk of death by 6 months (95% CI 1.47--6.98, p = 0.003) following adjustment for treatment arm and AKI status.

Survival data were not available at 6 months follow up for 16 children lost to follow up (LTFU) and 19 children \> 5 years of age and not followed to 6 months (according to the study protocol). To evaluate whether the association between CHI3L1 and 6 month mortality was robust to various assumptions a sensitivity analysis was performed first assuming all children \< 5 years of age LTFU died (Table [3](#Tab3){ref-type="table"}, model 1). Then all children \< 5 years of age LTFU were assumed to have survived (model 2). Assuming all children \< 5 years of age LTFU died, log~10~(CHI3L1) was associated with a 2.13-fold increased risk of death (1.18, 3.84, p = 0.012, model 1), and a 3.11-fold increased risk of death (1.38--6.99, p = 0.006, model 2) if all children \< 5 years of age LTFU survived. This analysis was then expanded to all children in the cohort (including children \> 5 years of age that were not followed). Assuming all children LTFU or \> 5 years of age died, log~10~(CHI3L1) was associated with a 1.99-fold increased risk of death by 6 months (1.22--3.25, p = 0.006, model 3). Assuming all children LTFU or \> 5 years of age survived, log~10~(CHI3L1) was associated with a 3.10-fold increased risk of death by 6 months (1.34--7.16, p = 0.008, model 4).Table 3Association between admission CHI3L1 levels and risk of deathIn-hospital mortalityAll cause 6 month mortalityRR (95% CI)p valueRR (95% CI)p valuePrimary models iNO group0.72 (0.28, 1.90)0.5120.85 (0.41, 1.76)0.670 AKI2.61 (0.85, 8.00)0.0941.28 (0.61, 2.68)0.521 Log~10~CHI3L14.10 (1.32, 12.75)0.0153.21 (1.47, 6.98)0.003Sensitivity analysis Model 1: children \< 5 years of age LTFU died^a^  iNO group----0.87 (0.52, 1.45)0.589  AKI----1.33 (0.76, 2.32)0.312  Log~10~CHI3L1----2.13 (1.18, 3.84)0.012 Model 2: children \< 5 years of age LTFU survived  iNO group----0.78 (0.37, 1.65)0.513  AKI----1.29 (0.61, 2.75)0.505  Log~10~CHI3L1----3.11 (1.38, 6.99)0.006 Model 3: children \< 5 years of age LTFU or \> 5 years died^a^  iNO group----0.76 (0.49, 1.17)0.213  AKI----1.21 (0.77, 1.90)0.419  Log~10~CHI3L1----1.99 (1.22, 3.25)0.006 Model 4: children \< 5 years of age LTFU or \> 5 years survived  iNO group----0.86 (0.40, 1.84)0.701  AKI----1.30 (0.60, 2.81)0.509  Log~10~CHI3L1----3.10 (1.34, 7.16)0.008Default model: generalized linear model with binomial family and log link*LFTU* lost to follow up^a^In the event of failed convergence a Poisson model with robust standard errors was used

CHI3L1 levels are associated with endothelial activation, inflammation and hemolysis {#Sec10}
------------------------------------------------------------------------------------

In order to explore potential pathophysiologic mechanisms linking elevated CHI3L1 and mortality in severe paediatric malaria, admission levels of CHI3L1 were compared with other host markers of immune and endothelial activation. CHI3L1 was correlated with pathways implicated in the pathobiology of severe malaria including markers of endothelial activation (angiopoietin-2, 0.43, p \< 0.0001; sICAM-1, 0.43, p \< 0.0001), markers of inflammation (CRP, 0.36, p \< 0.0001; CXCL10/IP-10, 0.26, p = 0.0008; sTREM-1, 0.23, p = 0.005); and markers of haemolysis (LDH, 0.28, p = 0.0004; haemopexin, − 0.23, p = 0.004; haem, 0.30, p = 0.0001).

Inhaled nitric oxide is associated with delayed recovery of CHI3L1 levels in children with severe malaria {#Sec11}
---------------------------------------------------------------------------------------------------------

LME models were used to explore the relationship between the longitudinal time course of CHI3L1 in patients in the placebo and treatment arms of the iNO trial. Assuming that differences at baseline between trial arms were due to chance alone (random allocation), we observed that CHI3L1 was elevated at baseline and decreased over the first 3 days of hospitalization at a different rate in children receiving iNO compared to placebo. The baseline (day 1) CHI3L1 concentration (estimate, 95% CI 213 ng/mL, 176--259) decreased by 34% per day (95% CI 31--38) in the placebo group and 29% per day (95% CI 25--33) in the iNO group (p = 0.007) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Treatment with inhaled nitric oxide is associated with a slower recovery of CHI3L1 levels. Line plots showing individual CHI3L1 trajectories for patients randomized to receive placebo (left) or inhaled nitric oxide (iNO, right). CHI3L1 levels for in-hospital mortality are depicted in red. The line for the random-intercept, random-slope linear mixed effects model is shown in black. The CHI3L1 concentration (estimate, 95% CI 213 ng/mL, 176--259) decreased by 34% per day (95% CI 31--38) in the placebo group and 29% per day (95% CI 25--33) in the iNO group (p = 0.0071, likelihood ratio test)

Longitudinal CHI3L1 levels are elevated in patients with AKI, in both placebo- and iNO-treated children with severe malaria {#Sec12}
---------------------------------------------------------------------------------------------------------------------------

AKI is associated with higher mortality in paediatric severe malaria \[[@CR6]\]; therefore, the relationship between longitudinal time course of CHI3L1 in patients with and without AKI was investigated. In an analysis including all trial participants and adjusting for the effect of iNO, AKI was associated with higher CHI3L1 levels (1.02-, 1.30-, and 2.50-fold higher in AKI grade 1, 2 and 3, respectively, relative to no AKI, p \< 0.0001, Fig. [3](#Fig3){ref-type="fig"}). To confirm the association between AKI and elevated CHI3L1 independent of iNO exposure, a subgroup analysis was performed using patients in the placebo arm of the trial: AKI grade 1, 2 and 3 was associated with CHI3L1 concentrations 0.94, 1.31, and 2.41-fold higher than patients without AKI, over the course of the first 3 days of hospitalization (p = 0.017).Fig. 3CHI3L1 levels are elevated over hospitalization according to the severity of acute kidney injury. Line plots showing individual CHI3L1 trajectories for patients according to the severity KDIGO-defined acute kidney injury (AKI). CHI3L1 levels for in-hospital mortality are depicted in red. The line for the linear mixed effects model is shown in black. Time, nitric oxide treatment arm, and AKI stage were entered as fixed effects. In this model, AKI grade 1, 2 and 3 was associated with CHI3L1 concentrations 1.02, 1.3, and 2.5-fold higher than patients without AKI, over the course of the first 3 days of hospitalization (p \< 0.0001)

Discussion {#Sec13}
==========

Acute kidney injury has recently become recognized as a common complication of paediatric severe malaria, but its pathogenesis is not well understood. In this study, elevated CHI3L1 levels at admission were associated with the severity of AKI. Using linear regression we explore the relationship between CHI3L1 levels and biomarkers of kidney function and found that CHI3L1 was significantly associated with increased Cystatin C following correction for age, sex and creatinine. CHI3L1 levels were associated with an increased risk of both in-hospital and long-term mortality independent of treatment arm and AKI. Importantly, using LME models to evaluate the longitudinal course of CHI3L1, administration of iNO was associated with prolonged elevation of CHI3L1 levels over the first 4 days of hospitalization. Further, there was a strong relationship between CHI3L1 levels and the severity of AKI that was independent of iNO treatment. These results suggest that CHI3L1 is an important biomarker of disease severity and mortality in paediatric severe malaria that is associated with kidney dysfunction as well as endothelial activation, inflammation and haemolysis. Additional studies are required to validate the relationship between CHI3L1 and AKI in severe malaria and investigate the association between CHI3L1 and established biomarkers of AKI.

CHI3L1 is a relatively new biomarker of AKI or altered renal function that has been investigated in the context of critical illness \[[@CR32], [@CR33]\], and sepsis \[[@CR34]\]. However, CHI3L1 has been predominantly investigated as a biomarker of AKI in urine rather than blood. CHI3L1 was identified in a urine proteomic screen in mice with kidney ischaemic reperfusion injury where a direct correlation was observed between the severity of kidney injury, CHI3L1 expression in the kidney, and levels in the urine \[[@CR20]\]. Studies of urinary CHI3L1 from donor kidneys suggested that CHI3L1 is a repair phase protein produced in response to tubular injury, and associated with recovery from AKI and delayed graft function \[[@CR35]\]. CHI3L1 expression has been reported on the surface of tubular epithelial cells, consistent with either uptake of filtered CHI3L1 or tubular cell secretion, and urinary CHI3L1 levels correlate with the severity of acute tubular necrosis \[[@CR35]\].

Studies in mice have shown that CHI3L1 plays a critical role in tissue repair and remodelling following pulmonary insult by limiting oxidative damage, stimulating alternative (M2) macrophage activation, and inhibiting apoptosis \[[@CR36]--[@CR38]\]. In the context of malaria, an increase of M2 monocytes in peripheral blood has been reported in children with severe malaria compared to healthy controls \[[@CR39]\]. Further, M2 monocytes were associated with increased expression of arginase 1, lower NOS2 mRNA, and lower plasma arginine \[[@CR39]\]. Additional studies are needed to delineate the role between CHI3L1, alternative macrophage activation in severe malaria and its relationship with AKI and NO bioavailability.

There are limited, and conflicting, data related to the relationship between CHI3L1 and NO. CHI3L1 has been positively correlated with NO levels in tissue culture supernatant from herniated lumbar discs \[[@CR40]\], and exhaled NO in children with severe therapy-resistant asthma \[[@CR41]\]. However, in patients with type 1 diabetes reduced NO in the blood correlated with elevated CHI3L1 \[[@CR42]\], and plasma CHI3L1 was negatively associated with nitric-oxide mediated vasodilatory capacity in adults with obstructive sleep apnea \[[@CR43]\]. In this study there was delayed CHI3L1 recovery in children receiving iNO independent of AKI-associated changes in CHI3L1, with CHI3L1 the only biomarker identified that has been shown to differ in response to iNO therapy \[[@CR27]\]. While there were differences in the rate of CHI3L1 recovery over the first 4 days of hospitalization associated with iNO therapy, the effect was not significant by day 14 suggesting that iNO results in a transient delay in the normalization of CHI3L1 levels.

Acute kidney injury is a common complication in severe malaria but its pathogenesis is unclear. Peripheral parasitaemia is not associated with worsening kidney function in children or adults with severe malaria \[[@CR6], [@CR10]\], but plasma HRP2 levels (reflecting total parasite biomass) are associated with worsening renal function, suggesting AKI is associated with the sequestered parasite biomass \[[@CR10]\]. Plasma suPAR---a marker of mononuclear cell activation---was elevated in adults with malaria-associated AKI \[[@CR10]\]. These results are consistent with post-mortem studies showing parasite sequestration and mononuclear cell infiltration in glomerular and peritubular capillaries \[[@CR44]\]. Neutrophil gelatinase-associated lipocalin (NGAL), an early marker of renal tubular damage, was elevated in adults with malaria-associated AKI \[[@CR10]\]. Oxidative stress and injury due to cell-free haemoglobin and haem from malaria-induced haemolysis may also contribute to tubular damage in malaria. In children with severe malaria, an increase in the haem to haemopexin ratio was observed over hospitalization in children with severe AKI (Stage 3 AKI) \[[@CR26]\]. In adults with severe malaria, reduced red blood cell deformability, and increased cell-free haemoglobin and lipid peroxidation (indicative of oxidative stress) were associated with AKI \[[@CR45]\].

While the mechanisms leading to severe malaria-associated AKI are not well understood, it is likely a heterogeneous syndrome characterized by reduced renal blood flow due to dehydration, hypotension, and impaired microcirculatory function as a result of parasite sequestration and reduced bioavailable nitric oxide. A subset of children may be at risk of developing direct tubular damage as a result of prolonged ischaemia, endothelial activation, inflammation, and cell-free haemoglobin and haem-mediated injury. In this cohort, an increase in CHI3L1 was associated with significant increases in creatinine, Cystatin C, and BUN by linear regression, and the relationship between CHI3L1 and Cystatin C remained significant following adjustment for creatinine. CHI3L1 levels also correlated with markers of immune activation (CRP, sTREM-1, CXCL10/IP-10), endothelial activation (Ang-2, sICAM-1), and haemolysis (LDH, haem, haemopexin), pathways of injury that are well described in paediatric severe malaria \[[@CR26]--[@CR28], [@CR46]--[@CR48]\]. As CHI3L1 is produced by tubular cells in response to injury and remodelling \[[@CR35]\], it may represent a novel biomarker of AKI in pediatric severe malaria. Additional studies are needed to delineate between CHI3L1 as a marker of inflammation versus AKI by comparing CHI3L1 levels to other established biomarkers of kidney injury (e.g. NGAL) that are well characterized in association with changes to kidney function. Further, additional research is needed to evaluate CHI3L1 over time as it relates to renal recovery and repair in both plasma and urine.

In this study elevated CHI3L1 levels at admission were a risk factor for in-hospital and all-cause 6 month mortality independent of kidney function and treatment group. These results are consistent with reports from adults where CHI3L1 is an independent predictor of all-cause mortality in type II diabetes \[[@CR49], [@CR50]\], heart failure \[[@CR51]\], and sepsis \[[@CR52]\]. Although CHI3L1 was strongly associated with AKI, which is an established risk factor for mortality in severe malaria, the relationship between CHI3L1 and increased risk of death was independent of AKI status suggesting CHI3L1 is not simply a biomarker of kidney function.

This study has several strengths including a randomized trial design with detailed clinical follow up and daily assessment of renal function and plasma CHI3L1 levels. Further, the majority of children were followed up to 6 months allowing us to evaluate the association between CHI3L1 and post-discharge mortality in children with severe malaria. Limitations include a lack of data on renal recovery and long-term renal function in the children. Further, urine was not collected to evaluate plasma versus urine levels of CHI3L1.

Conclusions {#Sec14}
===========

In this study, CHI3L1 was validated as an independent biomarker of morbidity and mortality in children with severe malaria that is associated with the presence and severity of AKI. This provides further evidence that AKI is an important complication in children with severe malaria associated with endothelial activation and inflammation. Additional studies to evaluate the long-term implications of AKI on kidney function in surviving children are urgently needed.
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===============

 {#Sec15}

**Additional file 1.** Dataset for malaria, CHI3L1, acute kidney injury, and mortality.

AKI

:   acute kidney injury

Ang-2

:   angiopoietin-2

GFR

:   glomerular filtration rate

KDIGO

:   kidney disease: improving global outcomes

NO

:   nitric oxide

iNO

:   inhaled nitric oxide

CHI3L1

:   chitinase-3-like 1

ARDS

:   acute respiratory distress syndrome

RDT

:   rapid diagnostic test

HRP2

:   histidine rich protein 2

pLDH

:   pan lactate dehydrogenase

ELISA

:   enzyme linked immunosorbent assay

LDH

:   lactate dehydrogenase

EDTA

:   ethylenediaminetetraacetic acid

LME

:   linear mixed effects

LTFU

:   lost to follow up
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